Brain Neoplasm Clinical Trial
Official title:
Investigation of Serial Advanced Magnetic Resonance Imaging (MRI) and Biofluid Biomarkers Predictive of Neurocognitive Decline Following Brain Radiation
This study determines whether non-invasive evaluation using repeated magnetic resonance imaging (MRI) scans and repeated blood biomarker measurements can be used to predict changes in a person's mental functions that result from radiation exposure to the brain. This study may let researchers monitor patient responses to treatment and the disease better and possibly make changes to patient treatment, if needed.
PRIMARY OBJECTIVE: I. To describe changes of image features on conventional T1- and T2- weighted imaging, and quantitative changes on multiparametric MRI including apparent diffusion coefficient (ADC), fractional anisotropy (FA), relative cerebral blood volume (rCBV), fractional volume of the extravascular, extracellular space (ve) and Ktrans (transfer constant that characterizes the diffusive transport of low-molecular weight gadolinium across the capillary endothelium) associated with neurocognitive changes following radiation. SECONDARY OBJECTIVES: I. To identify biofluid biomarkers at baseline and dynamics of biomarkers after radiation exposure that are associated with neurocognitive changes. II. To model a composite early biomarker (baseline or within 3 weeks of the start of radiotherapy) that incorporates the most promising imaging and biofluid biomarkers to predict for later neurocognitive decline. III. To evaluate the relationship between the delivered radiation dosimetry to brain subregions and patterns of neurocognitive decline in order to inform potential subregions of focus for future pre-clinical and clinical investigation. IV. To evaluate the relationship between quantitative changes on multiparametric MRI including apparent diffusion coefficient (ADC), fractional anisotropy (FA), relative cerebral blood volume (rCBV), fractional volume of the extravascular, extracellular space (ve) and Ktrans (transfer constant that characterizes the diffusive transport of low-molecular weight gadolinium across the capillary endothelium) with radiation dosimetry. EXPLORATORY OBJECTIVE: I. To explore changes on advanced MR measurements of structural connectomics, functional connectomics, working memory network, cerebrovascular reactivity (CVR), cerebral blood flow (CBF) and brain metabolism associated with neurocognitive changes following radiation. OUTLINE: Patients undergo multiparametric MRI with contrast at baseline, 3 weeks during radiotherapy, and at 1, 3, 6, 12, and 24 months post-radiotherapy. Patients undergo multiparametric MRI without contrast at 1, 2, 4, 5, and 6 weeks during radiotherapy. Patients may undergo functional MRI at baseline and 6 months post-radiotherapy. Patients also complete questionnaires and undergo collection of blood samples at baseline, weekly through week 6 during radiotherapy, and at 1, 3, 6, 12, and 24 months post radiotherapy. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00001972 -
PET Scan of Brain Metabolism in Relation to Age and Disease
|
N/A | |
Completed |
NCT02798406 -
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
|
Phase 2 | |
Terminated |
NCT02855086 -
Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery
|
Phase 1/Phase 2 | |
Terminated |
NCT00638963 -
Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2)
|
Phase 2 | |
Withdrawn |
NCT03234309 -
Ferumoxytol in Magnetic Resonance Imaging of Pediatric Patients With Brain Tumors
|
Phase 2 | |
Completed |
NCT00178295 -
Radiation-Induced Cytokine Cascades and Their Correlation With Central Nervous System Injury
|
N/A | |
Recruiting |
NCT04810871 -
Surgical Resection of Latent Brain Tumors Prior to Recurrence
|
N/A | |
Recruiting |
NCT02800486 -
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
|
Phase 2 | |
Completed |
NCT01621295 -
Assessing the Patient Experience in Cancer Care
|
N/A | |
Completed |
NCT02964416 -
Single Dose Tramadol Effect on Extubation Response and Quality of Emergence Post-supratentorial Intracranial Surgery
|
Phase 4 | |
Completed |
NCT00001574 -
A Pilot Study of 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Pediatric Patients With Primary and Metastatic Brain Tumors
|
||
Recruiting |
NCT02861898 -
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
|
Phase 1/Phase 2 | |
Completed |
NCT00040573 -
Safety and Tolerability Study of 131I-TM-601 to Treat Adult Patients With Recurrent Glioma.
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04553757 -
Seizure Control as a New Metric in Assessing Efficacy of Tumor Treatment in Patients With Low Grade Glioma
|
||
Recruiting |
NCT02754544 -
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
|
N/A | |
Recruiting |
NCT03216148 -
18F-FET PET in Childhood Brain Tumours
|
Phase 2 | |
Completed |
NCT00001171 -
Evaluation of Factors in Human Brain Tumors
|
N/A | |
Withdrawn |
NCT01413438 -
Bevacizumab With or Without Surgery for Adult Glioblastomas
|
Phase 2 | |
Not yet recruiting |
NCT05516485 -
Measuring Brain Tumor Consistency Using Magnetic Resonance Elastography
|
N/A | |
Recruiting |
NCT02639325 -
Tumor Related Epilepsy
|